The earnings call highlights significant strategic progress through the acquisition of Melinta, strong financial results, and clinical advancements. However, increased operating expenses and limited visibility on the LDO rollout present challenges.

Company Guidance -

Q3 2025

During the call, CorMedix Inc. provided detailed guidance for its financial performance following the acquisition of Melinta Therapeutics. The company expects full-year 2025 revenue for Melinta to be between $125 million and $135 million, with the combined company's projected revenue ranging from $305 million to $335 million. DefenCath, CorMedix's lead product, is anticipated to contribute $180 million to $200 million of net sales. The acquisition is projected to be accretive to EPS by double digits in 2026, with significant near-term operating expense synergies estimated at $35 million to $45 million. CorMedix also highlighted potential peak annual sales for REZZAYO, an expanded indication product, exceeding $200 million if approved. Additionally, the company is guiding for pro forma fully synergized adjusted EBITDA for 2025 between $150 million and $170 million.

Acquisition of Melinta Therapeutics

CorMedix announced the acquisition of Melinta Therapeutics, which is expected to be transformational, creating a diversified specialty pharmaceutical company. The acquisition is anticipated to be near-term accretive with double-digit EPS accretion in 2026, and expected to drive revenue growth.

Financial Performance

CorMedix reported net income of $19.8 million in Q2 2025, compared to a net loss of $14.2 million in Q2 2024. This improvement was driven by commercial sales of DefenCath.

Revenue Guidance

Projected full-year combined 2025 revenue of $305 million to $335 million, with Melinta contributing $125 million to $135 million. DefenCath net sales are expected to contribute $180 million to $200 million.

Clinical Progress

Progress on Phase III study for DefenCath in reducing CLABSI in adult patients, with multiple sites running and patients enrolled. Pediatric study for CRBSI reduction in pediatric patients has begun enrollment.

Cormedix (CRMD) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

CRMD Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 06, 2025	2025 (Q3)	0.30 / -	-0.05	―	―	―
Aug 07, 2025	2025 (Q2)	0.19 / 0.29	-0.25	216.00% (+0.54)	―	―
May 06, 2025	2025 (Q1)	0.26 / 0.30	-0.25	220.00% (+0.55)	―
Mar 25, 2025	2024 (Q4)	0.13 / 0.22	-0.26	184.62% (+0.48)	―
Oct 30, 2024	2024 (Q3)	-0.12 / -0.05	-0.17	70.59% (+0.12)	―
Aug 14, 2024	2024 (Q2)	-0.25 / -0.25	-0.25	0.00% (0.00)	―
May 09, 2024	2024 (Q1)	-0.28 / -0.25	-0.24	-4.17% (-0.01)	―
Mar 12, 2024	2023 (Q4)	-0.20 / -0.26	-0.2	-30.00% (-0.06)	―
Nov 14, 2023	2023 (Q3)	-0.21 / -0.17	-0.17	0.00% (0.00)	―
Aug 08, 2023	2023 (Q2)	-0.24 / -0.25	-0.19	-31.58% (-0.06)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

CRMD Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$11.95	$10.81	-9.54%
May 06, 2025	$9.03	$11.16	+23.59%
Mar 25, 2025	$10.77	$7.34	-31.85%
Oct 30, 2024	$12.97	$10.05	-22.51%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Cormedix Inc. (CRMD) report earnings?

Cormedix Inc. (CRMD) is schdueled to report earning on Nov 06, 2025, TBA (Confirmed).

What is Cormedix Inc. (CRMD) earnings time?

Cormedix Inc. (CRMD) earnings time is at Nov 06, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is CRMD EPS forecast?

CRMD EPS forecast for the fiscal quarter 2025 (Q3) is 0.3.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing